Background:
Symptomatic early onset pulmonary events (EOPEs) were observed in 3% to 6% of patients within 1 week of starting brigatinib at 90 mg daily for 7 days followed by 180 mg daily.
We conducted a prospective observational cohort study to measure pulmonary function changes on initiating brigatinib.
Used by permission: Terry L. Ng, MD, The Ottawa Hospital
International Association for the Study of Lung Cancer, Published by Elsevier Inc. All rights reserved. ISSN: 1556-0864